Treating Morbid Extreme Obesity.
A first-of-its-kind graft that curbs the edacity by electrically stimulating stomach nerves was approved Wednesday by the US Food and Drug Administration. The Maestro Rechargeable System is intended to look after morbid (extreme) obesity, gubbins manufacturer EnteroMedics Inc said in its application for FDA approval. The implant sends electrical signals to nerves around the inclination that help control digestion anti arthritis battle plan. These signals hunk the nerves, decreasing hunger pangs and making the person feel full.
The FDA approved the motto for use in people 18 and older who have a body-mass index (BMI) of 35 to 45 and at least one other obesity-related condition, such as pattern 2 diabetes. BMI is a ratio that determines body fat based on a person's peak and weight. For example, a person who's 5 feet, 8 inches lanky and weighs 230 pounds has a BMI of 35 grimstad. People with a BMI of 30 or higher are considered obese, according to the US Centers for Disease Control and Prevention.
People receiving a Maestro root also must have tried and failed to capitulate weight with a traditional weight loss program, the FDA said. The stratagem is the first FDA-approved obesity device since 2007. In clinical trials, individuals with a Maestro implant lost an average 8,5 percent more weight after one year than others who received a forgery implant. About half of the implanted patients lost at least 20 percent of their surfeit weight, and 38 percent lost at least 25 percent of their over-abundance weight.
EnteroMedics reported that people with fake implants regained about 40 percent of the incline they had lost within six months of the trial's end, while the people with the Maestro device appeared to allow their weight loss. According to the CDC, more than one-third of all US adults are obese, and people with plumpness are at increased risk of heart disease, stroke, type 2 diabetes and certain cancers.
And "Obesity and its coupled medical conditions are major public health problems," Dr William Maisel, head scientist in the FDA's Center for Devices and Radiological Health, said in an intercession news release. "Medical devices can help physicians and patients to develop comprehensive corpulence treatment plans". As part of the FDA approval, Minnesota-based EnteroMedics must conduct a five-year post-approval about that will follow at least 100 patients and collect additional safety and effectiveness data.
Showing posts with label device. Show all posts
Showing posts with label device. Show all posts
Sunday, 16 June 2019
Tuesday, 1 August 2017
New treatment for migraine
New treatment for migraine.
The US Food and Drug Administration has approved the head motto aimed at easing the pain of migraines preceded by aura - sensory disturbances that develop just before an attack. About a third of migraine sufferers experience auras. The Cerena Transcranial Magnetic Stimulator would be obtained through prescription, the FDA said in a proclamation released Friday Dec, 2013. Patients use both hands to hold the apparatus against the back of their head and press a button so that the trade mark can release a pulse of magnetic energy how to order vigrx plus in montana. This pulse stimulates the brain's occipital cortex, which may stay or ease migraine pain.
And "Millions of people suffer from migraines, and this different device represents a new treatment option for some patients," Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health, said in the statement restore cream psio. The agency's authorization is based on a sample involving 201 patients who had suffered moderate-to-strong migraine with aura.
The US Food and Drug Administration has approved the head motto aimed at easing the pain of migraines preceded by aura - sensory disturbances that develop just before an attack. About a third of migraine sufferers experience auras. The Cerena Transcranial Magnetic Stimulator would be obtained through prescription, the FDA said in a proclamation released Friday Dec, 2013. Patients use both hands to hold the apparatus against the back of their head and press a button so that the trade mark can release a pulse of magnetic energy how to order vigrx plus in montana. This pulse stimulates the brain's occipital cortex, which may stay or ease migraine pain.
And "Millions of people suffer from migraines, and this different device represents a new treatment option for some patients," Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health, said in the statement restore cream psio. The agency's authorization is based on a sample involving 201 patients who had suffered moderate-to-strong migraine with aura.
Sunday, 21 May 2017
Implantable Devices Are Not A Panacea, But The Ability To Relieve Migraine Attacks
Implantable Devices Are Not A Panacea, But The Ability To Relieve Migraine Attacks.
An implantable gambit private in the nape of the neck may common more headache-free days for people with severe migraines that don't respond to other treatments, a original study suggests. More than 36 million Americans get migraine headaches, which are marked by profound pain, sensitivity to light and sound, nausea and vomiting, according to the Migraine Research Foundation vitorun com. Medication and lifestyle changes are the first-line treatments for migraine, but not person improves with these measures.
The St Jude Medical Genesis neurostimulator is a short, chiffon strip that is implanted behind the neck. A battery group is then implanted elsewhere in the body. Activating the device stimulates the occipital nerve and can dull the pain of migraine headache worldplusmed.net. "There are a large number of patients for whom nothing works and whose lives are ruined by the routine pain of their migraine headache, and this device has the potential to help some of them," said observe author Dr Stephen D Silberstein, director of the Jefferson Headache Center in Philadelphia.
The study, which was funded by coat of arms manufacturer St Jude Medical Inc, is slated for performance on Thursday at the International Headache Congress in Berlin, and is the largest study to date on the device. The fellowship is now seeking approval for the device in Europe and then plans to submit their data to the US Food and Drug Administration for endorsement in the United States.
Researchers tested the new device in 157 kinsmen who had severe migraines about 26 days out of each month. After 12 weeks, those who received the creative device had seven more headache-free days per month, compared to one more headache-free day per month seen middle people in the control group.
Individuals in the control arm did not receive stimulation until after the firstly 12 weeks. Study participants who received the stimulator also reported less severe headaches and improvements in their superiority of life. After one year, 66 percent of people in the study said they had smashing or good pain relief.
The pain reduction seen in the study did fall short of FDA standards, which muster for a 50 percent reduction in pain. "The device is invisible to the eye, but not to the touch". The implantation routine involves local anesthesia along with conscious sedation so you are awake, but not fully aware.
There may be some calming pain associated with this surgery. Study co-author Dr Joel Saper, be wrecked and director of Michigan Head Pain and Neurological Institute in Ann Arbor, and a associate of the advisory board for the Migraine Research Foundation, said this therapy could be an important option for some bourgeoisie with migraines.
An implantable gambit private in the nape of the neck may common more headache-free days for people with severe migraines that don't respond to other treatments, a original study suggests. More than 36 million Americans get migraine headaches, which are marked by profound pain, sensitivity to light and sound, nausea and vomiting, according to the Migraine Research Foundation vitorun com. Medication and lifestyle changes are the first-line treatments for migraine, but not person improves with these measures.
The St Jude Medical Genesis neurostimulator is a short, chiffon strip that is implanted behind the neck. A battery group is then implanted elsewhere in the body. Activating the device stimulates the occipital nerve and can dull the pain of migraine headache worldplusmed.net. "There are a large number of patients for whom nothing works and whose lives are ruined by the routine pain of their migraine headache, and this device has the potential to help some of them," said observe author Dr Stephen D Silberstein, director of the Jefferson Headache Center in Philadelphia.
The study, which was funded by coat of arms manufacturer St Jude Medical Inc, is slated for performance on Thursday at the International Headache Congress in Berlin, and is the largest study to date on the device. The fellowship is now seeking approval for the device in Europe and then plans to submit their data to the US Food and Drug Administration for endorsement in the United States.
Researchers tested the new device in 157 kinsmen who had severe migraines about 26 days out of each month. After 12 weeks, those who received the creative device had seven more headache-free days per month, compared to one more headache-free day per month seen middle people in the control group.
Individuals in the control arm did not receive stimulation until after the firstly 12 weeks. Study participants who received the stimulator also reported less severe headaches and improvements in their superiority of life. After one year, 66 percent of people in the study said they had smashing or good pain relief.
The pain reduction seen in the study did fall short of FDA standards, which muster for a 50 percent reduction in pain. "The device is invisible to the eye, but not to the touch". The implantation routine involves local anesthesia along with conscious sedation so you are awake, but not fully aware.
There may be some calming pain associated with this surgery. Study co-author Dr Joel Saper, be wrecked and director of Michigan Head Pain and Neurological Institute in Ann Arbor, and a associate of the advisory board for the Migraine Research Foundation, said this therapy could be an important option for some bourgeoisie with migraines.
Tuesday, 12 November 2013
New Methods Of Diagnosis Of Stroke
New Methods Of Diagnosis Of Stroke.
The important to correctly diagnosing when a cover of dizziness is just vertigo or a life-threatening stroke may be surprisingly simple: a pair of goggles that measures glad eye movement at the bedside in as little as one minute, a new study contends. "This is the gold study demonstrating that we can accurately discriminate strokes and non-strokes using this device," said Dr David Newman-Toker, diva author of a paper on the technique that is published in the April issue of the newspaper Stroke bigger. Some 100000 strokes are misdiagnosed as something else each year in the United States, resulting in 20000 to 30000 deaths or unembroidered physical and speech impairments, the researchers said.
As with ticker attacks, the key to treating stroke and potentially saving a person's life is speed. Magnetic resonance imaging (MRI), the prevalent gold standard for assessing stroke, can take up to six hours to whole and costs $1200, said Newman-Toker, who is an associate professor of neurology and otolaryngology at Johns Hopkins Hospital in Baltimore rxlistbox com. Sometimes multitude don't even get as far as an MRI, and may be sent effectively with a first "mini stroke" that is followed by a devastating second stroke, he added.
The new study findings come with some significant caveats, however. For one thing, the library was a small one, involving only 12 patients. "It is preposterous for a small study to prove 100 percent accuracy," said Dr Daniel Labovitz, conductor of the Stern Stroke Center at Montefiore Medical Center in New York City, who was not twisted with the study. About 4 percent of dizziness cases in the danger room are caused by stroke.
The other caveat is that the device is not yet approved in the United States for diagnosing stroke. The US Food and Drug Administration only recently gave it okay for use in assessing balance. It has been on tap in Europe for that purpose for about a year. The device - known as a video-oculography implement - is a modification of a "head impulse test," which is used regularly for people with chronic dizziness and other inner ear-balance disorders.
The important to correctly diagnosing when a cover of dizziness is just vertigo or a life-threatening stroke may be surprisingly simple: a pair of goggles that measures glad eye movement at the bedside in as little as one minute, a new study contends. "This is the gold study demonstrating that we can accurately discriminate strokes and non-strokes using this device," said Dr David Newman-Toker, diva author of a paper on the technique that is published in the April issue of the newspaper Stroke bigger. Some 100000 strokes are misdiagnosed as something else each year in the United States, resulting in 20000 to 30000 deaths or unembroidered physical and speech impairments, the researchers said.
As with ticker attacks, the key to treating stroke and potentially saving a person's life is speed. Magnetic resonance imaging (MRI), the prevalent gold standard for assessing stroke, can take up to six hours to whole and costs $1200, said Newman-Toker, who is an associate professor of neurology and otolaryngology at Johns Hopkins Hospital in Baltimore rxlistbox com. Sometimes multitude don't even get as far as an MRI, and may be sent effectively with a first "mini stroke" that is followed by a devastating second stroke, he added.
The new study findings come with some significant caveats, however. For one thing, the library was a small one, involving only 12 patients. "It is preposterous for a small study to prove 100 percent accuracy," said Dr Daniel Labovitz, conductor of the Stern Stroke Center at Montefiore Medical Center in New York City, who was not twisted with the study. About 4 percent of dizziness cases in the danger room are caused by stroke.
The other caveat is that the device is not yet approved in the United States for diagnosing stroke. The US Food and Drug Administration only recently gave it okay for use in assessing balance. It has been on tap in Europe for that purpose for about a year. The device - known as a video-oculography implement - is a modification of a "head impulse test," which is used regularly for people with chronic dizziness and other inner ear-balance disorders.
Subscribe to:
Posts (Atom)